{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:26Z","timestamp":1781049446847,"version":"3.54.1"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing\/line of therapy of ILI has not been defined. This study evaluates ILI as first-line, second-line, or third or later-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review included all patients with unresectable ITM who underwent ILI from 2006-2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 130 patients were identified, 61% female, median age of 71 (31-89) years. Median follow-up was 37.5 months. ILI was first-line therapy in 80% (n = 104), second-line in 15% (n = 19), and third or later-line in 5.4% (n = 7). Overall response rate (ORR) and complete response (CR) rates for ILI as any line of therapy were 74% and 41%, respectively. ORR for ILI as first, second, or third or later-line therapy were 78%, 63%, and 57%, respectively. CR rates for ILI as first, second, or third or later-line therapy were 42%, 37%, and 43%, respectively. There were no significant differences in ORR, progression-free survival (PFS), overall survival, or disease-free survival between therapy lines. Median PFS for ILI as first, second, or third or later-line therapy were 6.9, 5.4, and 18\u00a0months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients responded well to ILI, whether or not they received previous therapies for unresectable ITM. First-line ILI appears to have a better ORR than later lines of ILI. Although sample size limited statistical significance, there was a 21% improvement in ORR when ILI was used as first-line vs third-line therapy, which is clinically meaningful. ILI is effective for unresectable melanoma ITM and can be used as salvage therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748241297326","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T21:03:36Z","timestamp":1730840616000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma"],"prefix":"10.1177","volume":"31","author":[{"given":"Aleena","family":"Boby","sequence":"first","affiliation":[{"name":"University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-7559","authenticated-orcid":false,"given":"Michelle M.","family":"Dugan","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helana","family":"Ghali","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaliz","family":"Aflatooni","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle K.","family":"DePalo","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA"},{"name":"Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-4468","authenticated-orcid":false,"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA"},{"name":"Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"bibr1-10732748241297326","unstructured":"Melanoma skin cancer statistics. https:\/\/www.Cancer.Org\/cancer\/types\/melanoma-skin-cancer\/about\/key-statistics.Html. Accessed December 1, 2023."},{"key":"bibr2-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4100-0"},{"key":"bibr3-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9717-9"},{"key":"bibr4-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.10.005"},{"key":"bibr5-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.041"},{"key":"bibr6-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000719"},{"key":"bibr7-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1111\/ans.14921"},{"key":"bibr8-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"bibr9-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"bibr10-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23702"},{"key":"bibr11-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.12.027"},{"key":"bibr12-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4169-5"},{"key":"bibr13-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-023-10234-6"},{"key":"bibr14-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-195810000-00009"},{"key":"bibr15-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07288-w"},{"key":"bibr16-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9"},{"key":"bibr17-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7511"},{"key":"bibr18-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9988-9"},{"key":"bibr19-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2011.03.013"},{"key":"bibr20-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246"},{"key":"bibr21-10732748241297326","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"bibr22-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25886"},{"key":"bibr23-10732748241297326","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020163"},{"key":"bibr24-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09051-y"},{"key":"bibr25-10732748241297326","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6107-9"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748241297326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748241297326","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748241297326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:14Z","timestamp":1777386194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748241297326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"alternative-id":["10.1177\/10732748241297326"],"URL":"https:\/\/doi.org\/10.1177\/10732748241297326","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"10732748241297326"}}